1. Home >
  2. Companies >
  3. Public >
  4. Life Science >
  5. France >
  6. Ipsen >
  7. M&A

Ipsen Mergers & Acquisitions

Ipsen M&A Summary

Ipsen has acquired 15 companies, including 6 in the last 5 years. A total of 5 acquisitions came from private equity firms. It has also divested 2 assets.

Ipsen’s largest acquisition to date was in 2023, when it acquired Albireo Pharma for $952M. Ipsen has acquired in 3 different US states, and 5 countries. The Company’s most targeted sectors include life science (100%).

M&A Summary

  • M&A Total Activity14
    • M&A Buy Activity12
    • M&A Sell Activity2
  • Total Sectors Invested 1
  • Total Countries Invested 5
  • M&A Buy/Sell Connections 9

Ipsen

Ipsen SA

65, quai Georges Gorse Cedex,
Boulogne-Billancourt, 92100
France,
+33 1 58 33 50 00
www.ipsen.com

All (14) Buy (12) Sell (2)
Date Target Value
$mlns 		Transaction Type Acquirer Seller SRC
Link
2025-10-22 Imcheck Therapeutics · Life Science
Marseilles, France · www.imchecktherapeutics.com

ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France.

Advisors: Centerview Partners , Dentons , Goodwin Procter 		- Add-on Acquisition

Ipsen
Advisor: A&O Shearman

Andera Partners PE

Bpifrance Investissement PE

EQT Life Sciences PE

GIMV PE


Try Mergr Free — See This and 220,453+
Other Company and Investor Profiles Today

Try free. Full access. Cancel anytime.

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
Try Free

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.8K Private Equity Firms
  • 214K M&A Transactions
  • 216K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 82K M&A Contacts
    (PE and M&A Advisors)

What next?

Try Free

Full access to Mergr's investor, acquirer, and transaction data starts here.

Mergr

Solution for

Product

Company

Legal